Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
about
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopyLeishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatmentIncreasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncomplianceAntimonial resistance in Leishmania donovani is associated with increased in vivo parasite burdenA screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hitIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesLeishmania donovani develops resistance to drug combinationsOver-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovaniFitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania majorDifferent Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct MechanismsDisruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasionA putative plant aminophospholipid flippase, the Arabidopsis P4 ATPase ALA1, localizes to the plasma membrane following association with a β-subunit.Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diaminesFluorescent labeling of Acanthamoeba assessed in situ from corneal sectioned microscopy.Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquineStructures, targets and recent approaches in anti-leishmanial drug discovery and development.Use of antimony in the treatment of leishmaniasis: current status and future directions.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in childrenIn vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococciDevelopment of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies.Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugsThe relationship between leishmaniasis and AIDS: the second 10 yearsPharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.Therapeutic options for visceral leishmaniasis.Drug resistance in visceral leishmaniasis.The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.ABC transporters involved in drug resistance in human parasites.Chemotherapy of leishmaniasis: present challenges.Evaluating drug resistance in visceral leishmaniasis: the challenges.Antimycobacterial and antileishmanial effects of microfungi isolated from tropical regions in México.Treatment of imported New World cutaneous leishmaniasis in Germany.In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmania infantum.Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.
P2860
Q24615049-F34032BC-147E-4322-90B3-F1BA15F7AD84Q28082283-D371D26A-DCAA-4F99-8B67-BC42C54F28B5Q28285948-3C1B4185-5243-49B7-868D-DCB6029809F2Q28476400-C9CF4746-66AA-4EDC-B0F6-EF03FDBC03F5Q28479211-5840B8A9-83FE-493D-9E0A-FEF084C6B7F7Q28482212-8783A22D-2B5E-4E2A-A3E4-3D4E79B5D55DQ28484463-1BF92C7C-BE87-4A56-A1F5-DF29DFE7C4B9Q28536134-B73A5600-ABB0-4DB6-AC44-C30758A74AD5Q28546940-BFD15473-1D83-41CA-AC63-52F2046CDF9BQ28554770-A0DECE6F-B333-4ED5-9594-4D0869097063Q33701743-CB7C6626-6AFC-4998-87DC-E0552572CAC6Q34238377-3E010770-0C62-476A-97EA-B0C1B1433E96Q34435696-E494C642-3800-489F-8C86-ABFE1F89CE86Q34452377-7F494AEF-C1A5-4F73-9D37-70C1A6C083E9Q35005213-10AA049F-86A9-440F-9EED-5F78C974F438Q35012968-E58DD609-27C4-4E95-A4B3-596D6D05BCB3Q35377767-A2ED5D86-6083-414E-94AF-A72844D974EDQ35606296-186A4923-BEC3-44D0-8495-59FA4BAF9762Q35694752-0166D5B2-B902-4211-8D3C-00F84767EACDQ35759108-95396739-0BF5-432B-91B2-6DFD606C7D97Q35960805-3C754F7F-CB07-4877-9E56-F7C53F2EC461Q36001763-4DC40157-0356-4F42-80D1-A5208C7F6C49Q36450807-B9E99088-B9B5-4754-A99F-2955519EB777Q36538814-CCAC3B58-0697-4C31-9D26-95E9DE2D52BCQ36803937-5D149254-804E-4E1A-A00C-C2CD42A0D2D5Q37072017-371BF0DD-8B49-4F59-95A0-E6A4F7FF912CQ37333942-99C56062-6E1D-478F-A274-A24E0EC6A32CQ37407549-E17A4E57-D25E-4A48-BF15-DDBD3B650A95Q37425218-DFB95929-0926-49BF-82EC-46DC12D0D4FBQ37615730-78502EF1-AC31-4283-8296-75E7326C3B2DQ37693923-893856AD-A0FF-4FEB-A472-C0A625078B1CQ37941754-C00AA5E4-807C-4962-B8A1-44A4BD36AA62Q39011875-2F85464D-6E42-4AD8-AB95-0289EB00EF9BQ39014583-63F06565-E17A-4CD7-92FF-9CB85CE1A389Q39016408-049BD02E-C0C1-4076-945B-6D4D33890348Q39048632-1A6C00C4-813D-4639-9C0E-265AED297A36Q39475712-5D90816B-EB2B-4532-859F-C86371DBC702Q40067217-E6754C7C-E305-4E3C-83E3-58AFDF8C28A0Q40084369-AF63B068-86BE-4444-967F-16A824EBD671Q40174125-3306B56E-9389-4F42-BCC4-D09AAE272FED
P2860
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Mechanisms of experimental res ...... Implications for clinical use.
@ast
Mechanisms of experimental res ...... Implications for clinical use.
@en
type
label
Mechanisms of experimental res ...... Implications for clinical use.
@ast
Mechanisms of experimental res ...... Implications for clinical use.
@en
prefLabel
Mechanisms of experimental res ...... Implications for clinical use.
@ast
Mechanisms of experimental res ...... Implications for clinical use.
@en
P2093
P1476
Mechanisms of experimental res ...... Implications for clinical use.
@en
P2093
F Javier Pérez-Victoria
Karin Seifert
María P Sánchez-Cañete
Santiago Castanys
Simon L Croft
P356
10.1016/J.DRUP.2006.04.001
P577
2006-02-01T00:00:00Z